Clinical Edge Journal Scan

Survival after CRS-HIPEC in synchronous vs metachronous peritoneal metastasis of CRC


 

Key clinical point: Patients with synchronous (s) vs metachronous (m) onset of colorectal peritoneal metastasis (PM) had poor overall survival (OS) after cytoreductive surgery (CRS) combined with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC); however, s-PM was not an independent predictor of OS.

Major finding: Patients with s-PM vs m-PM had a significantly shorter median OS (28 vs 33 months; P = .045). However, rather than the onset of PM ( P = .193), factors such as poor differentiation of the primary tumor (adjusted hazard ratio [aHR] 1.95; P = .001), N stage (aHR 1.76; P = .020), and peritoneal cancer index (aHR 1.07; P < .001) independently predicted OS.

Study details: Findings are from a retrospective study including 390 patients who underwent complete CRS-HIPEC for colorectal s-PM (diagnosed during presentation/staging/primary surgery; n = 179) or m-PM (diagnosed during follow-up; n = 211).

Disclosures: No source of funding was reported. the authors declared no conflicts of interest.

source: dietz mv et al. survival outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with synchronous versus metachronous onset of peritoneal metastases of colorectal carcinoma. Ann Surg Oncol. 2022 (May 5). Doi: 10.1245/s10434-022-11805-9

Recommended Reading

Gastric cancer: Trastuzumab does not benefit rescued HER2-positive patients
MDedge Hematology and Oncology
Gastric cancer: Apatinib and PD-1 inhibitors show response in real world study
MDedge Hematology and Oncology
Radical surgery improves survival in older patients with gastric cancer
MDedge Hematology and Oncology
CRC screening: Blood test accuracy compared to colonoscopy
MDedge Hematology and Oncology
Alarming increase in esophageal cancer in middle-aged adults
MDedge Hematology and Oncology
Metastatic CRC: Phase 3 supports extension of sequential treatment over combination
MDedge Hematology and Oncology
KEYNOTE-177 delivers final results with pembrolizumab vs chemotherapy for MSI-H or dMMR mCRC
MDedge Hematology and Oncology
Unresectable mCRC: Final survival outcomes with first-line trifluridine/tipiracil plus bevacizumab in TASCO1
MDedge Hematology and Oncology
Proton pump inhibitors curb capecitabine efficacy in stage II-III CRC
MDedge Hematology and Oncology
Proton pump inhibitors curb capecitabine efficacy in stage II-III CRC
MDedge Hematology and Oncology